PMID- 35002700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220111
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered 
      Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.
PG  - 759262
LID - 10.3389/fphar.2021.759262 [doi]
LID - 759262
AB  - Background: Cardio-renal profiles are available from cardiovascular outcome 
      trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Methods: A 
      comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL 
      databases was conducted. Randomized controlled cardiovascular outcome trials of 
      type 2 diabetes mellitus (T2DM) patients administered GLP-1 RAs were included. 
      The following primary outcomes were examined: cardiovascular death, major adverse 
      cardiovascular events (MACE), myocardial infarction, stroke, mortality, heart 
      failure, hypoglycemia, pancreatitis, and thyroid carcinoma. Secondary outcomes 
      included: composite kidney outcome, worsening kidney function, macroalbuminuria, 
      and retinopathy. Results: Seven trials involving 56,004 patients and eight 
      interventions were identified. Albiglutide was associated with fewer MACE and 
      myocardial infarction events compared with lixisenatide. Lixisenatide was related 
      to a greater number of stroke events and cardiovascular deaths compared to 
      once-weekly semaglutide and oral semaglutide, respectively. Improved mortality 
      was associated with oral semaglutide compared with once-weekly semaglutide, 
      albiglutide, dulaglutide, exenatide, or lixisenatide. Risks of heart failure, 
      thyroid carcinoma, and pancreatitis were similar among all the treatments. 
      Weighting of the nine primary outcomes identified oral semaglutide as first among 
      the eight treatments examined. Among three of the secondary outcomes, once-weekly 
      semaglutide ranked first. Better composite kidney outcome was observed with 
      once-weekly semaglutide than with dulaglutide or exenatide; once-weekly 
      semaglutide improved macroalbuminuria compared with exenatide or lixisenatide; 
      and albiglutide, exenatide, and placebo was associated with fewer cases of 
      retinopathy compared with once-weekly semaglutide. Meanwhile, kidney function was 
      less likely to worsen with dulaglutide than with lixisenatide or placebo. 
      Conclusion: Semaglutide should be considered when GLP-1 RAs are indicated for 
      T2DM patients.
CI  - Copyright (c) 2021 Zhuo, Lin, Zhou, Gao, Shao, Fang, Tian, Ding and Liu.
FAU - Zhuo, Chuanjun
AU  - Zhuo C
AD  - National of Metabolism Management Center (MMC), Tianjin Medical University 
      Affiliated Tianjin Fourth Center Hospital, Nankai University Affiliated Hospital, 
      Tianjin Fourth Center Hospital, Tianjin, China.
AD  - Department of Endocrinology and Metabolism, Tianjin Medical University General 
      Hospital, Tianjin, China.
AD  - Department of Psychiatric-Neuroimaging-Genetics Laboratory (PNGC_Lab), Tianjin 
      Mental Health Center, Tianjin Medical University, Tianjin, China.
AD  - Department of Psychiatry, Wenzhou Seventh Peoples Hospital, Wenzhou, China.
FAU - Lin, Chongguang
AU  - Lin C
AD  - Department of Psychiatry, Wenzhou Seventh Peoples Hospital, Wenzhou, China.
FAU - Zhou, Chunhua
AU  - Zhou C
AD  - Department of Pharmacy, The First Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Gao, Xiangyang
AU  - Gao X
AD  - Big Data Analysis Center of Health Management Institute, The Second Medical 
      Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA 
      General Hospital, Beijing, China.
FAU - Shao, Hailin
AU  - Shao H
AD  - National of Metabolism Management Center (MMC), Tianjin Medical University 
      Affiliated Tianjin Fourth Center Hospital, Nankai University Affiliated Hospital, 
      Tianjin Fourth Center Hospital, Tianjin, China.
FAU - Fang, Tao
AU  - Fang T
AD  - National of Metabolism Management Center (MMC), Tianjin Medical University 
      Affiliated Tianjin Fourth Center Hospital, Nankai University Affiliated Hospital, 
      Tianjin Fourth Center Hospital, Tianjin, China.
FAU - Tian, Hongjun
AU  - Tian H
AD  - National of Metabolism Management Center (MMC), Tianjin Medical University 
      Affiliated Tianjin Fourth Center Hospital, Nankai University Affiliated Hospital, 
      Tianjin Fourth Center Hospital, Tianjin, China.
FAU - Ding, Li
AU  - Ding L
AD  - Department of Endocrinology and Metabolism, Tianjin Medical University General 
      Hospital, Tianjin, China.
FAU - Liu, Ming
AU  - Liu M
AD  - Department of Endocrinology and Metabolism, Tianjin Medical University General 
      Hospital, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20211224
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8741261
OTO - NOTNLM
OT  - cardio-renal benefit
OT  - glucagon-like peptide-1 receptor agonist
OT  - network meta-analysis
OT  - semaglutide
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/11 06:00
MHDA- 2022/01/11 06:01
PMCR- 2021/12/24
CRDT- 2022/01/10 09:08
PHST- 2021/08/16 00:00 [received]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2022/01/10 09:08 [entrez]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/01/11 06:01 [medline]
PHST- 2021/12/24 00:00 [pmc-release]
AID - 759262 [pii]
AID - 10.3389/fphar.2021.759262 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Dec 24;12:759262. doi: 10.3389/fphar.2021.759262. 
      eCollection 2021.